Adding a Muscle Targeting Antibody to Semaglutide Cut Lean Mass Loss from 7.4% to 2.9% in a Phase 2 Trial

Adults taking semaglutide alone lost 7.4 percent of their lean mass over the course of a phase 2 trial. Lean mass fell 2.9 percent in the combination group, against 7.4 percent with semaglutide 2.4 milligrams alone, a statistically significant difference. Rapid weight loss without attention to strength carries its own risks, especially for older adults where falls become the downstream concern. In this trial, semaglutide 2.4 milligrams alone reduced lean mass by 7.4 percent. Investigators reported improved physical function alongside preserved lean mass, but whether that advantage persists over years has not been established.